Shanghai Pharmaceuticals Holding Co., Ltd. (600849.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

288.45B

Net Income (TTM)

4.75B

Op. CF (TTM)

9.91B

Latest newsMore news →

Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical received the National Medical Products Administration's drug supplementary application approval notice, granting consistency evaluation for its lincomycin hydrochloride injection generic drug.10d ago

Shanghai Pharmaceuticals Holding Co., Ltd. signed a strategic cooperation framework agreement with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences on September 7, 2026, to collaborate on innovative drug R&D and technology transfer.13d ago

Latest newsMore news →

Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical received the National Medical Products Administration's drug supplementary application approval notice, granting consistency evaluation for its lincomycin hydrochloride injection generic drug.10d ago Shanghai Pharmaceuticals Holding Co., Ltd. signed a strategic cooperation framework agreement with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences on September 7, 2026, to collaborate on innovative drug R&D and technology transfer.13d ago Shanghai Pharmaceuticals' subsidiary Shanghai Hefeng Pharmaceutical received NMPA approval for promethazine hydrochloride injection to pass generic consistency evaluation.27d ago